Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update
<!-- Name:DistributionId Value:8788461 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Matinas
Matinas BioPharma Provides Business Update and 2023 Strategic Outlook
<!-- Name:DistributionId Value:8739090 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Matinas BioPharma Announces Collaboration with National Resilience to Explore and…
BEDMINSTER, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of…
Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent…
EnACT Phase 2 study of MAT2203 in cryptococcal meningitis met its primary endpoint with 95% two-week patient survival in the Cohort 4 all-oral regimen Phase 3 pivotal trial of MAT2203 for…
Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of…
Two-week survival in Cohort 4 (all-oral regimen) was 95% in 40 patients receiving MAT2203 Mean Early Fungicidal Activity (EFA) of the rate of yeast clearance in cerebrospinal fluid…
Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference
BEDMINSTER, N.J., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of…
Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has…
BEDMINSTER, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular…
Matinas BioPharma Announces Positive Opinion by the European Medicines Agency on…
BEDMINSTER, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of…